Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | CD22 | P20273 | 1/20 | 0.46 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.46 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.45 |
| ▸ | RNF168 | Q8IYW5 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24974781 | 0.94 | SIRT2 (0.48) | GBA1PKMOPRM1CD22LYPLA2 | |
| SCHEMBL24974743 | 0.94 | OPRM1 (0.48) | GBA1PKMOPRM1CD22LYPLA2 | |
| SCHEMBL24974633 | 0.91 | PKM (0.47) | GBA1PKMOPRM1CD22LYPLA2 | |
| SCHEMBL24974638 | 0.89 | PKM (0.47) | GBA1PKMOPRM1CD22LYPLA2 | |
| SCHEMBL24974776 | 0.89 | PKM (0.49) | GBA1PKMOPRM1CD22LYPLA2 | |
| SCHEMBL24974540 | 0.84 | PKM (0.47) | PKMOPRM1CD22LYPLA2SENP1 | |
| SCHEMBL19006139 | 0.82 | OPRM1 (0.57) | GBA1PKMOPRM1CD22LYPLA2 | |
| SCHEMBL24974801 | 0.81 | LYPLA2 (0.47) | GBA1PKMOPRM1CD22LYPLA2 | |
| SCHEMBL21122079 | 0.81 | PKM (0.48) | GBA1PKMOPRM1CD22LYPLA2 | |
| SCHEMBL24974361 | 0.78 | OPRM1 (0.48) | GBA1PKMOPRM1CD22LYPLA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | GBA1 293/4885PKM 3656/4885OPRM1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.